Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net loss	$ (4,886,169)	$ (4,425,914)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	10,724	13,788
Amortization	318,609	318,609
Lease expense (benefit)	5,377	(1,732)
Loss on disposal of property and equipment	135,600
Loss on operating lease right-of-use asset - lease abandonment	146,795
Loss on operating lease right-of-use asset - lease termination settlement	53,692
Stock-based compensation – employees	589,950	956,700
Stock-based compensation – non-employees	279,000
Shares issued related to lease termination settlement	50,700
Non-cash services expense	19,000
Foreign exchange (gain) loss	(25,659)	38,909
Changes in operating assets and liabilities which (used) provided cash
Other receivable	144,244	(3,129)
Accounts payable	20,439	(2,534)
Accounts payable – related parties	8,347
Accrued interest – related and non-related parties	2,687,145	2,435,298
Accrued expenses	93,600	123,856
Net cash used in operating activities	(399,306)	(546,149)
Cash flows used in investing activities
Advances to CEN Biotech Ukraine LLC	(105,000)	(160,000)
Proceeds from sale of equipment	1,801
Net cash used in investing activities	(103,199)	(160,000)
Cash flows provided by financing activities
Issuance of convertible notes	499,000	689,554
Repayment of convertible notes		(6,000)
Issuance of convertible notes – related parties		20,000
Net cash provided by financing activities	499,000	703,554
Net decrease in cash and cash equivalents	(3,505)	(2,595)
Cash and cash equivalents, beginning of period	3,757	3,193
Cash and cash equivalents, end of period	252	598
Supplemental cash flows disclosures
Cash paid for interest	41,527	38,913
Non-cash transactions - investing and financing activities
Issuance of note payable for services	19,000
Issuance of common stock - settlement of accrued liability	$ 58,500